- Patients must not have had prior therapy for CLL (except palliative steroids or treatment of autoimmune complications of CLL with rituximab or steroids)
|
-
Patients must not have any history of Richter's transformation or prolymphocytic leukemia (prolymphocytes in blood >/= 55%)
|
-
Patients with class III or class IV heart failure by New York Heart Association, those with unstable angina, and those with uncontrolled arrhythmia are not eligible
|
-
Patients who have had a myocardial infarction, intracranial bleed, or stroke within the past 6 months are not eligible
|
-
Patients must not be receiving active systemic anticoagulation with heparin or warfarin. Patients on warfarin must discontinue the drug for at least 10 days prior to registration on the study
|
-
Chronic concomitant treatment with strong inhibitors of CYP3A4/5 is not allowed on this study. Patients on strong CYP3A inhibitors must discontinue the drug for 14 days prior to registration on the study
|
-
Chronic concomitant treatment with strong CYP3A4/5 inducers is not allowed. Patients must discontinue the drug 14 days prior to registration on the study
|
-
Patients must not require more than 20 mg prednisone or equivalent corticosteroid daily
|
-
Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics
|
-
Patients must be able to swallow capsules and not have the following conditions: disease significantly affecting gastrointestinal absorption, resection of the stomach or small bowel, partial or complete bowel obstruction
|
-
Patients must not have a known allergy to mannitol
|
-
"Please contact study team for more eligibility criteria."
|